Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Enveric Biosciences Q3 2026 Results: Net Loss of $2.55M, Loss Widens

Enveric Biosciences reported a net loss of $7.21 million for the nine months ended September 30, 2026, compared to $6.58 million in the prior year period, driven by increased research and development costs. The company strengthened its cash position to $5.61 million through various financing activities, including private placements and warrant exercises, resulting in a total shareholders' equity of $5.73 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-2.5-1.9
Net income-2.5-1.9
EPS (diluted, $ a share)$-0.57$-10.81

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: ENVB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Enveric Biosciences, Inc.: key numbers

Share price
$1.44Close, Nov 16
Market cap
$6.45M
Shares outstanding
4.48MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Enveric Biosciences, Inc.

All →
4:06 PM ET 8-K
Financial Results

Enveric Biosciences Financial Results

Enveric Biosciences reported financial results for the third quarter of 2026 and provided a corporate update on its lead candidate EB-003. The company is completing final IND-enabling activities for EB-003, a non-hallucinogenic neuroplastogenic candidate, with plans for an IND submission and Phase 1 clinical trial.

Term
Q3 2026

“Our focus during the third quarter was advancing final IND-enabling activities for EB-003 as we prepare for the planned IND submission and first-in-human Phase 1 clinical trial of our lead non-hallucinogenic, neuroplastogenic candidate.”

Joseph Tucker, Ph.D., Chief Executive Officer of Enveric

“The growing body of preclinical evidence reinforces our confidence in this opportunity as we complete the final IND-enabling activities and prepare to advance EB-003 toward first-in-human clinical development.”

Joseph Tucker, Ph.D., Chief Executive Officer of Enveric

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.